Analysis of circulating EVs from patients with prostate cancer found tumor-related DNA, in particular TP53 and PTEN mutations [Table 1, n = 4 (Lázaro-Ibáñez et al., 2014)], further confirmed in very few samples from metastatic castration-resistant cancers (n = 4; Vagner et al., 2018). This evidence concerns the gene TP53 and prostate cancer.